Evidence map›Paper›PMID 40801273›Full record

ReviewHuman vaccines & immunotherapeutics2025

Innovative adjuvant strategies for next-generation pertussis vaccines.

Ge Yu, Wenqi Yang, Yubin Ma, Ning Zhang, Di Tang, Ye Jin, Liang Shi, Mengshu Wang, Dawei Liu, Changying Xue and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ge YuState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Wenqi YangState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Yubin MaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Ning ZhangState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Di TangState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Ye JinSchool of Life and Health, Dalian University, Dalian, China.
Liang ShiQuality System, Changchun BCHT Biotechnology Co., Changchun, China.
Mengshu WangQuality System, Changchun BCHT Biotechnology Co., Changchun, China.
Dawei LiuQuality System, Changchun BCHT Biotechnology Co., Changchun, China.
Changying XueSchool of Bioengineering, Dalian University of Technology, Dalian, China.
Bingbing SunState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.ORCID 0000-0002-5444-5078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccinePertussis VaccineVaccine DevelopmentWhooping CoughAnimalsBordetella pertussisHumansVaccines, AcellularAdjuvants, ImmunologicAdjuvants, VaccinePertussis VaccineVaccines, Acellularadjuvantscombined vaccinesformulationmucosal immunityPertussis vaccinesvaccine stability

Identifiers

PMID40801273
PMCPMC12351750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.